The global Cancer Diagnostics market Size is valued at 110.25 billion in 2024 and is predicted to reach 204.49 billion by the year 2031 at a 6.5% CAGR during the forecast period for 2025-2034.
One of the essential factors of the Cancer Diagnostics market growth throughout the anticipated period is the rise in cancer cases worldwide. Diagnostic test technological developments are also anticipated to support industry expansion. Additionally, it is projected that supportive government measures and growing awareness will contribute to growth during the forecast period. For instance, the Biden-Harris administration has established a goal to improve the understanding of people living with and surviving cancers and reduce the cancer mortality rate by 50% over the next 25 years.
The prevalence of cancer has been rising at an alarming pace, making it one of the major causes of death worldwide. Healthcare professionals are concentrating on creating efficient screening and treatment solutions to monitor prevalence levels. The success of treatment plans is increased by early screening. As a result, healthcare organizations and industry participants are pushing regular checkups and screenings through various awareness campaigns. For instance, the HHS announced financing of USD 5 million in March 2022 to enhance equity in cancer screening at health centers.
The Cancer Diagnostics market is segmented by product, technology, application, and end-user. Based on product, the market is segregated into consumables, instruments, imaging instruments, and biopsy instruments. By the technology, the market is segmented into IVD Testing, imaging, and biopsy technology. By application, the market is segmented as breast cancer, lung cancer, colorectal cancer, melanoma, and others. By end user, the market is further segmented into hospitals and diagnostics laboratories.
The consumables section held the largest share, and it is projected that it will remain in this position for the duration of the forecast. The segment is developing as a result of rising consumable usage, rising R&D costs, an increase in the number of elderly people, and the introduction of technologically sophisticated diagnostic kits and reagents.
Due to reasons like the growing use of in-vitro diagnostics, IVD testing held the greatest proportion. The market is extending as a result of an increasing number of in vitro diagnostics products being introduced by key industry participants. For instance, Invitae introduced LiquidPlex Dx and FusionPlex Dx in Europe in February 2022. In Europe, patients will have easier access to cancer diagnostics thanks to the product launch. In addition, the completely automated Idylla GeneFusion Panel for non-small cell lung cancer was introduced by Biocartis Group NV in June 2022. Unlike more current testing procedures, which typically require days or even weeks to get findings, the panel is intended for use in clinical laboratories and delivers comprehensive test results in 180 minutes.
The largest portion was held by North America. The market in this area is being driven by significant companies engaging in more strategic actions. For instance, Resolution Bioscience Inc. was purchased by Agilent in March 2021. The company's capabilities in NGS-based cancer diagnostics are expanded and complemented by the acquisition, which also equips the business with cutting-edge technology to meet the demands of the expanding precision medicine market.
| Report Attribute | Specifications |
| Market size value in 2024 | USD 110.25 Bn |
| Revenue forecast in 2034 | USD 204.49 Bn |
| Growth rate CAGR | CAGR of 6.5% from 2025 to 2034 |
| Quantitative units | Representation of revenue in US$ Billion, and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Product, Technology, Application, And End-User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; Japan; Brazil; Mexico; France; Italy; Spain; China; India; South Korea; Southeast Asia |
| Competitive Landscape | GE Healthcare, Abbott Laboratories, Hologic Inc., Agilent Technologies Inc., Roche Diagnostics, FUJIFILM Corporation, Danaher Corporation, DiaSorin S.P.A., Myriad Genetics Inc., Siemens AG, BD, Cancer Diagnostics Inc., AMOY Diagnostics Co Ltd., Quidel Corporation, BiocartisNV, Excat Science. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Cancer Diagnostics Market By Product-
Cancer Diagnostics Market By Technology-
Cancer Diagnostics Market By Application-
Cancer Diagnostics Market By End User-
Cancer Diagnostics Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer Diagnostics Market Snapshot
Chapter 4. Global Cancer Diagnostics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis
5.1. by Product & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product:
5.2.1. Consumables
5.2.1.1. Antibodies
5.2.1.2. Kits & Reagents
5.2.1.3. Probes
5.2.1.4. Other Consumables
5.2.2. Instruments
5.2.2.1. Pathology-based Instruments
5.2.2.1.1. Slide Staining Systems
5.2.2.1.2. Tissue Processing Systems
5.2.2.1.3. Cell Processors
5.2.2.1.4. PCR Instruments
5.2.2.1.5. NGS Instruments
5.2.2.1.6. Microarrays
5.2.2.1.7. Other Pathology-based Instruments
5.2.2.2. Imaging Instruments
5.2.2.2.1. CT Systems
5.2.2.2.2. Ultrasound Systems
5.2.2.2.3. MRI Systems
5.2.2.2.4. Mammography Systems
5.2.2.2.5. Nuclear Imaging Systems
5.2.3. Biopsy Instruments
Chapter 6. Market Segmentation 2: by Technology Estimates & Trend Analysis
6.1. by Technology & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Technology:
6.2.1. IVD Testing
6.2.1.1. Polymerase Chain Reaction (PCR)
6.2.1.2. In Situ Hybridization (ISH)
6.2.1.3. Immunohistochemistry (IHC)
6.2.1.4. Next-generation Sequencing (NGS)
6.2.1.5. Microarrays
6.2.1.6. Flow Cytometry
6.2.1.7. Immunoassays
6.2.1.8. Other IVD Testing Technologies
6.2.2. Imaging
6.2.2.1. Magnetic Resonance Imaging (MRI)
6.2.2.2. Computed Tomography (CT)
6.2.2.3. Positron Emission Tomography (PET)
6.2.2.4. Mammography
6.2.2.5. Ultrasound
6.2.3. Biopsy Technique
Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Application:
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Melanoma
7.2.5. Other Cancers
Chapter 8. Market Segmentation 4: by End-user Estimates & Trend Analysis
8.1. by End-user & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-user:
8.2.1. Hospitals
8.2.2. Diagnostic Laboratories
Chapter 9. Cancer Diagnostics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.1.2. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.1.3. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.1.4. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.1.5. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.2.2. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.2.3. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.4. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.2.5. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.3.2. Asia Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.3.3. Asia-Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.4. Asia-Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.3.5. Asia Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.4.2. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.4.3. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.4. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.4.5. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.5.2. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.5.3. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.4. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.5.5. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Abbott Laboratories,
10.2.2. Agilent Technologies Inc.,
10.2.3. AMOY Diagnostics Co Ltd.,
10.2.4. Astellas Pharma Inc. (Japan)
10.2.5. BD
10.2.6. BiocartisNV,
10.2.7. bioMérieux SA (France)
10.2.8. Bristol-Myers Squibb Company (U.S.)
10.2.9. Cancer Diagnostics Inc.,
10.2.10. Danaher Corporation,
10.2.11. DiagnoCure Inc. (Canada)
10.2.12. DiaSorin S.P.A.,
10.2.13. Excat Science
10.2.14. F. Hoffmann-La Roche Ltd.
10.2.15. FUJIFILM Corporation,
10.2.16. GE Healthcare
10.2.17. Genomic Health, Inc. (U.S.)
10.2.18. GSK plc. (U.K.)
10.2.19. Hologic, Inc.
10.2.20. Illumina, Inc.
10.2.21. Koninklijke Philips N.V. (Philips)
10.2.22. Lilly (U.S.)
10.2.23. Merck KGaA, (Germany)
10.2.24. Myriad Genetics Inc.,
10.2.25. Novartis AG (Switzerland)
10.2.26. Pfizer, Inc. (U.S.)
10.2.27. Qiagen N.V.
10.2.28. Quest Diagnostics Incorporated. (U.S.)
10.2.29. Quidel Corporation,
10.2.30. Roche Diagnostics,
10.2.31. Siemens Healthcare GmbH
10.2.32. Thermo Fisher Scientific, Inc.
10.2.33. Other Prominent Players
Cancer Diagnostics Market By Product-
Cancer Diagnostics Market By Technology-
Cancer Diagnostics Market By Application-
Cancer Diagnostics Market By End User-
Cancer Diagnostics Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-